Advertisement

Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study

  • Vanja ZeremskiEmail author
  • Kathleen Jentsch-Ullrich
  • Christoph Kahl
  • Martin Mohren
  • Judith Eberhardt
  • Thomas Fischer
  • Enrico Schalk
Original Article

Abstract

Despite bendamustine-rituximab (BR) showed disappointing efficacy in diffuse large B cell lymphoma (DLBCL), it is still occasionally used as first-line treatment in older DLBCL patients instead of recommended R-CHOP. This multicentre, retrospective study was aimed to clarify circumstances in which BR may be justified in this setting. Patients ≥ 65 years with ECOG performance status (PS) ≥ 2 or ≥ 75 years regardless of PS were included. A total of 140 patients were analysed (BR, 68; R-CHOP, 72). BR patients were older (p < 0.001) and were diagnosed more often with high-risk disease (p = 0.03); no difference regarding comorbidities or PS was seen. Compared with R-CHOP, BR was associated with marked inferior overall survival (OS) (16.3 vs. 75.4 months; p = 0.006) and progression-free survival (PFS) (11.0 vs. 62.3 months; p < 0.001). In multivariate analysis, only high age-adjusted Charlson Comorbidity Index (aaCCI) was associated with inferior PFS in R-CHOP patients (hazard ratio 2.67; p = 0.012). Comparing the subgroup of BR and R-CHOP patients with high aaCCI, there was no difference in OS (p = 0.73) or PFS (p = 0.75). Due to the observed non-superiority of R-CHOP in older DLBCL patients with comorbidities, we propose that this subgroup may be treated alternatively with BR, whereas all other older patients are clearly R-CHOP candidates.

Keywords

Diffuse large B cell lymphoma Bendamustine R-CHOP Older patients Comorbidities 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

Funding information

This research was supported by a grant from the German Research Foundation (DFG; SFB854).

Compliance with ethical standards

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

References

  1. 1.
    Saygin C, Jia X, Hill B, Dean R, Pohlman B, Smith MR, Jagadeesh D (2017) Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. Am J Hematol 92:989–996.  https://doi.org/10.1002/ajh.24819 CrossRefPubMedGoogle Scholar
  2. 2.
    Morrison VA, Shou Y, Bell JA, Hamilton L, Ogbonnaya A, Raju A, Hennenfent K, Eaddy M, Galaznik A (2019) Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol 15:1021–1034.  https://doi.org/10.2217/fon-2018-0788 CrossRefPubMedGoogle Scholar
  3. 3.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994CrossRefGoogle Scholar
  4. 4.
    Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW (2005) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55:231–240.  https://doi.org/10.1016/j.critrevonc.2005.04.008 CrossRefPubMedGoogle Scholar
  5. 5.
    Pfreundschuh M (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116:5103–5110.  https://doi.org/10.1182/blood-2010-07-259333 CrossRefPubMedGoogle Scholar
  6. 6.
    Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ (2014) Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122:3145–3151.  https://doi.org/10.1002/cncr.30173 CrossRefGoogle Scholar
  7. 7.
    Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trneny M, Wedding U, Fields P, ESMO Lymphoma Consensus Conference Panel Members (2018) ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol 29:544–562.  https://doi.org/10.1093/annonc/mdx413 CrossRefPubMedGoogle Scholar
  8. 8.
    Kumar A, Fraz MA, Usman M, Malik SU, Ijaz A, Durer C, Durer S, Tariq MJ, Khan AY, Qureshi A, Faridi W, Nasar A, Anwer F (2018) Treating diffuse large B cell lymphoma in the very old or frail patients. Curr Treat Options in Oncol 19:50.  https://doi.org/10.1007/s11864-018-0565-6 CrossRefGoogle Scholar
  9. 9.
    Boslooper K, Kibbelaar R, Storm H, Veeger NJ, Hovenga S, Woolthuis G, van Rees B, de Graaf E, van Roon E, Kluin-Nelemans HC, Joosten P, Hoogendoorn M (2014) Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma 55:526–532.  https://doi.org/10.3109/10428194.2013.810737 CrossRefPubMedGoogle Scholar
  10. 10.
    Byun JM, Lee JO, Kang B, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Bang SM, Lee JS (2016) Diffuse large B-cell lymphoma in the elderly: real world outcomes of immunochemotherapy in Asian population. Clin Lymphoma Myeloma Leuk 16:503–510.  https://doi.org/10.1016/j.clml.2016.06.003 CrossRefPubMedGoogle Scholar
  11. 11.
    Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417–1423.  https://doi.org/10.1182/blood-2004-08-3175 CrossRefPubMedGoogle Scholar
  12. 12.
    Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H, Groupe d’Etude des Lymphomes de l’Adulte (GELA) investigators (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460–468.  https://doi.org/10.1016/S1470-2045(11)70069-9 CrossRefPubMedGoogle Scholar
  13. 13.
    Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D (2014) De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 32:282–287.  https://doi.org/10.1200/JCO.2013.49.7586 CrossRefPubMedGoogle Scholar
  14. 14.
    Shen QD, Zhu HY, Wang L, Fan L, Liang JH, Cao L, Wu W, Xia Y, Li JY, Xu W (2018) Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematol 5:e261–e269.  https://doi.org/10.1016/S2352-3026(18)30054-1 CrossRefPubMedGoogle Scholar
  15. 15.
    Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, Dürk H, Rost A, Neise M, von Grünhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 23:3383–3389.  https://doi.org/10.1200/JCO.2005.08.100 CrossRefPubMedGoogle Scholar
  16. 16.
    Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM (2014) Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944–2952.  https://doi.org/10.1182/blood-2013-11-531327 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 22:1839–1844.  https://doi.org/10.1093/annonc/mdq671 CrossRefPubMedGoogle Scholar
  18. 18.
    Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC (2016) A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol 175:281–289.  https://doi.org/10.1111/bjh.14232 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Storti S, Spina M, Pesce EA, Salvi F, Merli M, Ruffini A, Cabras G, Chiappella A, Angelucci E, Fabbri A, Liberati AM, Tani M, Musuraca G, Molinari A, Petrilli MP, Palladino C, Ciancia R, Ferrario A, Gasbarrino C, Monaco F, Fraticelli V, De Vellis A, Merli F, Luminari S (2018) Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. Haematologica 103:1345–1350.  https://doi.org/10.3324/haematol.2017.186569 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hammersen FJ, Sommer M, Gössel C, Teichgräber U, Hahnfeld S, Scholl S, Fricke HJ, Wedding U, Ekkehard E, Iver P, Merz H, Hochhaus A, La Roséee P (2013) Safety and efficacy of bendamustine in patients with aggressive non-Hodgkin lymphomas (NHL). Blood 122:4371CrossRefGoogle Scholar
  21. 21.
    Cheng CL, Liu JH, Chou SC, Yao M, Tang JL, Tien HF (2018) Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. Eur J Haematol 101:28–37.  https://doi.org/10.1111/ejh.13069 CrossRefPubMedGoogle Scholar
  22. 22.
    Hammersen FJ, Rüthrich MM, Wedding U, Sommer M, Hochhaus A, La Rosee P (2018) Comparison of R-miniCHOP with R-Bendamustine (R-B) in diffuse large B-cell Lymphoma (DLBCL) in elderly and comorbid patients. Oncol Res Treat 41(suppl 4):44 abstract P173Google Scholar
  23. 23.
    Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251CrossRefGoogle Scholar
  24. 24.
    World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194.  https://doi.org/10.1001/jama.2013.281053 CrossRefGoogle Scholar
  25. 25.
    Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244–1253.  https://doi.org/10.1200/JCO.1999.17.4.1244 CrossRefPubMedGoogle Scholar
  26. 26.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586.  https://doi.org/10.1016/j.hoc.2007.06.011 CrossRefPubMedGoogle Scholar
  27. 27.
    Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S (2014) Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist 19:1249–1257.  https://doi.org/10.1634/theoncologist.2014-0113 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Diem S, Ess S, Cerny T, Früh M, Hitz F (2014) Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med 25:577–582.  https://doi.org/10.1016/j.ejim.2014.05.001 CrossRefPubMedGoogle Scholar
  29. 29.
    Tien YY, Link BK, Brooks JM, Wright K, Chrischilles E (2015) Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. Leuk Lymphoma 56:65–71.  https://doi.org/10.3109/10428194.2014.903589 CrossRefPubMedGoogle Scholar
  30. 30.
    Juul MB, Jensen PH, Engberg H, Wehberg S, Dessau-Arp A, Haziri D, Kristensen HB, Baech J, Schurmann L, Clausen MR, Valentin R, Knudsen LM, Munksgaard L, El-Galaly TC, Frederiksen H, Larsen TS (2018) Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. Eur J Cancer 99:86–96.  https://doi.org/10.1016/j.ejca.2018.05.006 CrossRefPubMedGoogle Scholar
  31. 31.
    Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, bendamustine, bendamustine, phase 3 non-inferiority trial. Lancet 381:1203–1210.  https://doi.org/10.1016/S0140-6736(12)61763-2 CrossRefPubMedGoogle Scholar
  32. 32.
    Bellera C, Praud D, Petit-Monéger A, McKelvie-Sebileau P, Soubeyran P, Mathoulin-Pélissier S (2013) Barriers to inclusion of older adults in randomised controlled clinical trials on non-Hodgkin’s lymphoma: a systematic review. Cancer Treat Rev 39:812–817.  https://doi.org/10.1016/j.ctrv.2013.01.007 CrossRefPubMedGoogle Scholar
  33. 33.
    Hamaker ME, Stauder R, van Munster BC (2014) On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? Ann Oncol 25:675–681.  https://doi.org/10.1093/annonc/mdt592 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    ClinicalTrials.gov (2019) https://clinicaltrials.gov (accessed at 11/06/2019)

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Haematology and OncologyOtto-von-Guericke University MagdeburgMagdeburgGermany
  2. 2.Health Campus Immunology, Infectiology and Inflammation (GC-I3), Medical CentreOtto-von-Guericke UniversityMagdeburgGermany
  3. 3.Private Practice for Haematology and OncologyMagdeburgGermany
  4. 4.Department of Haematology, Oncology and Palliative CareKlinikum MagdeburgMagdeburgGermany
  5. 5.Department of Hematology and OncologyJohanniter KrankenhausStendalGermany

Personalised recommendations